全文获取类型
收费全文 | 125909篇 |
免费 | 12955篇 |
国内免费 | 4302篇 |
专业分类
耳鼻咽喉 | 821篇 |
儿科学 | 1889篇 |
妇产科学 | 1444篇 |
基础医学 | 23132篇 |
口腔科学 | 3027篇 |
临床医学 | 7830篇 |
内科学 | 19371篇 |
皮肤病学 | 2261篇 |
神经病学 | 13362篇 |
特种医学 | 3138篇 |
外国民族医学 | 35篇 |
外科学 | 9734篇 |
综合类 | 13032篇 |
现状与发展 | 23篇 |
预防医学 | 4594篇 |
眼科学 | 1338篇 |
药学 | 20553篇 |
39篇 | |
中国医学 | 4609篇 |
肿瘤学 | 12934篇 |
出版年
2024年 | 250篇 |
2023年 | 2052篇 |
2022年 | 3754篇 |
2021年 | 5629篇 |
2020年 | 4757篇 |
2019年 | 4985篇 |
2018年 | 4821篇 |
2017年 | 4858篇 |
2016年 | 4640篇 |
2015年 | 5296篇 |
2014年 | 7715篇 |
2013年 | 8295篇 |
2012年 | 7148篇 |
2011年 | 8451篇 |
2010年 | 6799篇 |
2009年 | 6865篇 |
2008年 | 6821篇 |
2007年 | 5896篇 |
2006年 | 5105篇 |
2005年 | 4624篇 |
2004年 | 3975篇 |
2003年 | 3501篇 |
2002年 | 2699篇 |
2001年 | 2221篇 |
2000年 | 1889篇 |
1999年 | 1721篇 |
1998年 | 1681篇 |
1997年 | 1618篇 |
1996年 | 1426篇 |
1995年 | 1325篇 |
1994年 | 1202篇 |
1993年 | 1130篇 |
1992年 | 882篇 |
1991年 | 790篇 |
1990年 | 676篇 |
1989年 | 586篇 |
1988年 | 547篇 |
1987年 | 517篇 |
1986年 | 620篇 |
1985年 | 868篇 |
1984年 | 801篇 |
1983年 | 622篇 |
1982年 | 621篇 |
1981年 | 524篇 |
1980年 | 483篇 |
1979年 | 391篇 |
1978年 | 243篇 |
1977年 | 206篇 |
1976年 | 214篇 |
1975年 | 133篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
52.
53.
ObjectiveThe purpose of this paper is to review the efficacy and safety profile in children treated with topical 0.03% Tacrolimus ointment for vernal keratoconjunctivitis in Middle East and to propose a treatment posology. According to recent studies, a complex non-IgE dependent mechanism plays a relevant role in the pathogenesis of vernal keratoconjunctivitis. Numerous cells and mediators have been found in the serum, conjunctiva and tears of patients with Vernal keratoconjunctivitis.DesignThis case series included 10 patients from a single centre, pediatric department of a tertiary hospital with active symptomatic vernal keratoconjunctivitis. All the patients had proliferative lesions and corneal involvement despite conventional medications, including topical steroids. All other medications, systemic and topical: steroids, antihistamines and cyclosporine, were unsuccessful. Patients were treated with topical 0.03% Tacrolimus ointment twice daily for 8 weeks and then once a day for the next two month followed by thrice a week for two months. The changes in symptoms and signs after treatment were evaluated, also the development of possible complications was assessed.ResultsThe results showed a significant reduction in signs and symptoms after 4 weeks of the treatment. Clinical resolution of giant papillae and corneal lesions were seen within eight weeks and no additional drug was required during that period, except tear substitutes. Treatment was continued for period of two months and then slowly reduced.ConclusionThe use of 0.03% Tacrolimus ointment is safe and effective in children refractory to conventional treatment of vernal keratoconjunctivitis even in high temperature climate as Middle East. Due to the effectiveness of the treatment, the dosage used may be proposed for conventional use. 相似文献
54.
55.
《Health Policy and Technology》2022,11(3):100647
BackgroundUnequal housing access resulted in more than 150 million homeless people worldwide, with millions more expected to be added every year due to the ongoing climate-related crises. Homeless population has a counterproductive effect on the social, psychological integration efforts by the community and exposure to other severe health-related issues. Geographic Information Systems (GIS) have long been applied in urban planning and policy, housing and homelessness, and health-related research.MethodsWe used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) method to systematically review 24 articles collected from multiple databases (n = 10) that focused on health-related issues among homeless people and used geospatial analysis techniques in their research.ResultsOur findings indicated a geographic clustering of case study locations– 26 out of the 31 case study sites are from the USA and Canada. Studies used spatial analysis techniques to identify hotspots, clusters and patterns of patient location and population distribution. Studies also reported relationships among the location of homeless shelters and substance use, discarded needles, different infectious and non-infectious disease clusters.ConclusionMost studies were restricted in analyzing and visualizing the patterns and disease clusters; however, geospatial analyses techniques are useful and offer diverse techniques for a more sophisticated understanding of the spatial characteristics of the health issues among homeless people. Better integration of GIS in health research among the homeless would help formulate sensible policies to counter health inequities among this vulnerable population group. 相似文献
56.
57.
58.
Yuan Peng Yuman Li Haiyan Cao Liu Hong Yu Wang Mingxing Xie 《Journal of ultrasound in medicine》2019,38(2):539-544
A pulmonary artery (PA) sling is a very rare congenital cardiovascular anomaly, and only a few studies have reported PA slings in fetuses. The relationship of the PA, aorta, ductus arteriosus, and trachea can be evaluated in the 3‐vessel and 3‐vessel and trachea views during fetal echocardiography. A PA sling can be detected by abnormal positioning of the left PA in relation to the trachea when sweeping from the 3‐vessel view cranially to the 3‐vessel and trachea view. Here we report 3 cases of fetal PA slings and their follow‐ups. Two cases were confirmed by postnatal echocardiography, and the other case was confirmed by a cardiovascular cast after pregnancy termination. We emphasize that the 3‐vessel and 3‐vessel and trachea views are of crucial importance in the prenatal diagnosis of a PA sling. 相似文献
59.
60.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.